Lupin's Trandolapril gets USFDA nod

Lupin, a pharmaceutical company, has recieved the required approval from the US Food and Drug Administration (USFDA) for multiple strengths of Trandolapril tablets used in the treatment of hypertension.

Kamal Sharma, managing director, Lupin, said, "We are delighted with the timely approval of Trandolapril tablets. This approval broadens our growing portfolio of cardiovascular medications".

The company has recieved approval for multiple strengths of 1mg, 2mg and 4mg.

This abbreviated new drug application (ANDA) - Trandolapril tablets, are the AB-rated generic equivalent of Abbott's Mavik tablets that are indicated for the treatment of hypertension.

According to IMS sales data, the Trandolapril tablets had annual sales of about 49 million dollar for 12 months ended in December 2006.

Earlier in May 31, the company had received USFDA approval for Cefadroxil capsules, an antibiotic used for treatment of infections caused by bacteria.